The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes.
Actual Study Start Date :
January 19, 2005
Actual Primary Completion Date :
September 28, 2005
Actual Study Completion Date :
October 14, 2005
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Currently being treated with Atorvastatin 10 mg for at least 6 weeks
Have Type 2 Diabetes
Weight must be stable for more than 6 weeks before entering the study
Consume more than 14 alcoholic drinks per week.
Pregnant or lactating
Have taken another investigation drug within 3 months of starting this study
History of congestive heart failure, heart attack, coronary artery bypass surgery